384 related articles for article (PubMed ID: 27363442)
1. Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the Engine Rather than the Drivers-A New Perspective?
Treps L; Conradi LC; Harjes U; Carmeliet P
Pharmacol Rev; 2016 Jul; 68(3):872-87. PubMed ID: 27363442
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
Bikfalvi A; Bicknell R
Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
[TBL] [Abstract][Full Text] [Related]
3. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease.
Goveia J; Stapor P; Carmeliet P
EMBO Mol Med; 2014 Sep; 6(9):1105-20. PubMed ID: 25063693
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism.
Stapor P; Wang X; Goveia J; Moens S; Carmeliet P
J Cell Sci; 2014 Oct; 127(Pt 20):4331-41. PubMed ID: 25179598
[TBL] [Abstract][Full Text] [Related]
5. Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective.
Missiaen R; Morales-Rodriguez F; Eelen G; Carmeliet P
Vascul Pharmacol; 2017 Mar; 90():8-18. PubMed ID: 28082117
[TBL] [Abstract][Full Text] [Related]
6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
7. Targeting fatty acid metabolism in cancer and endothelial cells.
Harjes U; Kalucka J; Carmeliet P
Crit Rev Oncol Hematol; 2016 Jan; 97():15-21. PubMed ID: 26558689
[TBL] [Abstract][Full Text] [Related]
8. Imaging tumor angiogenesis.
Red-Horse K; Ferrara N
J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Draoui N; de Zeeuw P; Carmeliet P
Open Biol; 2017 Dec; 7(12):. PubMed ID: 29263247
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Regulation of Angiogenesis in Diabetes and Aging.
Sawada N; Arany Z
Physiology (Bethesda); 2017 Jul; 32(4):290-307. PubMed ID: 28615313
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
[TBL] [Abstract][Full Text] [Related]
13. Development of new drugs in angiogenesis.
Ziche M; Donnini S; Morbidelli L
Curr Drug Targets; 2004 Jul; 5(5):485-93. PubMed ID: 15216914
[TBL] [Abstract][Full Text] [Related]
14. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
15. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Welti J; Loges S; Dimmeler S; Carmeliet P
J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
[TBL] [Abstract][Full Text] [Related]
16. Vascular Detransformation for Cancer Therapy.
Fan Y
Trends Cancer; 2019 Aug; 5(8):460-463. PubMed ID: 31421902
[TBL] [Abstract][Full Text] [Related]
17. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenic metabolism in disease.
Li X; Carmeliet P
Science; 2018 Mar; 359(6382):1335-1336. PubMed ID: 29567696
[No Abstract] [Full Text] [Related]
19. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?
Cascone T; Heymach JV
J Clin Oncol; 2012 Feb; 30(4):441-4. PubMed ID: 22184396
[No Abstract] [Full Text] [Related]
20. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
